A NIR-Ⅱ fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer.
2/5 보강
TL;DR
A near-infrared-II (NIR-II) fluorescent molecular probe developed by conjugating a CDK4/6 inhibitor with human serum albumin and facilitating its self-assembly with human serum albumin is established as a promising tool for the early assessment of therapeutic efficacy and the identification of resistance.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: HR+/HER2-breast cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Furthermore, the probe could distinguish between CDK4/6 inhibitor-sensitive and -resistant tumors, with resistant models showing a consistently low signal. Our findings establish HSA-ICi as a promising tool for the early assessment of therapeutic efficacy and the identification of resistance, potentially facilitating timely treatment adaptation for patients with HR+/HER2-breast cancer.
OpenAlex 토픽 ·
Advanced Breast Cancer Therapies
Cancer-related Molecular Pathways
Advanced Biosensing Techniques and Applications
A near-infrared-II (NIR-II) fluorescent molecular probe developed by conjugating a CDK4/6 inhibitor with human serum albumin and facilitating its self-assembly with human serum albumin is established
APA
Yi-Yang Gao, Kangliang Lou, et al. (2026). A NIR-Ⅱ fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer.. Cancer letters, 646, 218429. https://doi.org/10.1016/j.canlet.2026.218429
MLA
Yi-Yang Gao, et al.. "A NIR-Ⅱ fluorescent probe for real-time visualization and early assessment of responses to CDK4/6 inhibitors in breast cancer.." Cancer letters, vol. 646, 2026, pp. 218429.
PMID
41825845 ↗
Abstract 한글 요약
The evaluation of therapeutic response to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer currently relies on anatomical imaging, which suffers from significant delays. To enable early and direct visualization of drug activity, we developed a near-infrared-II (NIR-II) fluorescent molecular probe, HSA-ICi, by conjugating a CDK4/6 inhibitor (Palbociclib or Ribociclib) with ICG and facilitating its self-assembly with human serum albumin. This probe demonstrated specific targeting to the CDK4/6-cyclin D complex, excellent biocompatibility, and high tumor accumulation in preclinical models. Crucially, HSA-ICi allowed non-invasive monitoring of pharmacodynamic response: a significant decrease in tumor fluorescence signal was detected via NIR-II imaging as early as one week after treatment initiation, preceding any measurable change in tumor volume by caliper or magnetic resonance imaging (MRI). This early signal reduction correlated with decreased pRB and Ki-67 expression in tumor tissues. Furthermore, the probe could distinguish between CDK4/6 inhibitor-sensitive and -resistant tumors, with resistant models showing a consistently low signal. Our findings establish HSA-ICi as a promising tool for the early assessment of therapeutic efficacy and the identification of resistance, potentially facilitating timely treatment adaptation for patients with HR+/HER2-breast cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.